Paul Capital Partners

Carbon Black, Inc. is a cybersecurity company that offers advanced security solutions to clients in the United States and internationally. Founded in 2002 and headquartered in Waltham, Massachusetts, the company provides a comprehensive platform known as the Cb Predictive Security Cloud, which leverages big data and analytics to enhance endpoint security. Carbon Black's suite of products includes endpoint detection and response solutions, antivirus software, threat hunting services, and real-time security operations capabilities. Its offerings help organizations predict, prevent, detect, respond to, and remediate cyber threats, including malware and ransomware attacks. The company serves a diverse clientele, including security-focused enterprises, government agencies, and small to mid-sized organizations. In January 2016, Carbon Black changed its name from Bit9, Inc. and has since established itself as a leader in the cybersecurity industry, providing innovative solutions to protect critical systems and data. As of October 2019, Carbon Black operates as a subsidiary of VMware, Inc.

Recyclebank is a company dedicated to promoting sustainability by incentivizing environmentally friendly behaviors. Through its social platform, Recyclebank rewards members for engaging in green actions, such as recycling and adopting sustainable practices. Users earn points by completing various challenges, which can be redeemed for discounts and deals from both local and national businesses. This approach not only fosters individual awareness and engagement in sustainable living but also aims to enhance community participation in recycling efforts. By encouraging people to make environmentally conscious choices, Recyclebank contributes to a broader goal of reducing waste and promoting a more sustainable future.

Tethys BioScience, Inc. is focused on the discovery, development, and commercialization of biological markers for diagnosing metabolic diseases, particularly diabetes. The company has developed the PreDx Diabetes Risk Test, which evaluates a combination of proteins and other blood-borne biomarkers associated with diabetes risk. Founded in 2002, Tethys BioScience is headquartered in Emeryville, California.

Phase III Development is a Software Engineering company with expertise in a wide variety of development technologies. The mission is to provide customers with innovative custom software solutions of superior quality. They deliver on budget and on time.

UCB is a Belgium-based biopharmaceutical company focused on developing therapies for central nervous system and immunology diseases. It maintains a broad portfolio across neurology and immunology, including treatments for epilepsy (Vimpat, Briviact, Keppra), Parkinson's disease and restless legs syndrome (Neupro), and autoimmune conditions such as inflammatory diseases (Cimzia) and psoriasis-related indications (bimekizumab, Evenity for osteoporosis). The company also markets medicines for allergies (Zyrtec, Xyzal), narcolepsy (Xyrem), and other conditions, and is pursuing innovative therapies such as Nayzilam for seizure clusters and newer agents like padsevonil, rozanolixizumab, UCB7858, UCB0599, and UCB0107. It engages in contract manufacturing and collaborates with academic and industry partners, including a multi-year collaboration with Stanford Medicine and partnerships with Sanofi, Amgen, Biogen, Otsuka, and doc.ai to advance patient value. Founded in 1928 and headquartered in Brussels, UCB integrates research, development, and manufacturing to address neurological and immune-related diseases worldwide.

SpePharm is a European specialty pharmaceutical company focused on acquiring, registering, and marketing high-value medicines primarily for the hospital market. The company specializes in oncology, hematology, and supportive care, offering medical products that aid in the local oral treatment and management of complications arising from radiotherapy or chemotherapy. SpePharm's management team possesses extensive global experience in the pharmaceutical sector, with a strong understanding of the European regulatory environment and a particular expertise in niche and orphan products. This strategic focus allows SpePharm to effectively address the needs of healthcare professionals and patients across Europe.

On-X Life Technologies Inc. is a company that specializes in the development, manufacture, and marketing of artificial heart valve replacement and repair products. The firm offers a diverse product portfolio that includes aortic and mitral heart valves with various sewing ring configurations, ascending aortic prostheses, and chordal repair products, among others. Additionally, On-X provides technical services related to carbon-based technology encompassing medical design, product development, and manufacturing. Founded in 1994 and headquartered in Austin, Texas, On-X Life Technologies aims to advance cardiovascular care through innovative medical devices. The company was formerly known as Medical Carbon Research Institute, L.L.C. and rebranded in June 2007.

Acorda Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders. Founded in 1995 and headquartered in Ardsley, New York, the company markets Ampyra (dalfampridine), an oral drug approved by the FDA to improve walking in patients with multiple sclerosis (MS). In Europe, this drug is marketed as Fampyra. Acorda also markets Selincro for alcohol dependence in Europe and Zanaflex Capsules for spasticity management. Additionally, the company develops Inbrija for treating OFF periods in Parkinson’s disease and ARCUS for acute migraine. Other pipeline products include rHIgM22 for MS and Cimaglermin alfa for heart failure. Acorda has collaborations with Biogen Inc. for Ampyra's development and commercialization.

Prism Pharmaceuticals, Inc. is an acute care pharmaceutical company founded in 2004 and based in King of Prussia, Pennsylvania. The company specializes in the development and commercialization of cardiovascular injectable products in the United States. Its notable offerings include NEXTERONE, an injectable formulation of amiodarone designed for the treatment of arrhythmias, and PM103, an intravenous version of clopidogrel bisulfate. Through its innovative products, Prism Pharmaceuticals aims to address critical needs in cardiovascular care.

Verus Pharmaceuticals is a pediatric-oriented company that identifies, develops, and delivers solutions to address the unmet medical needs of children and those who care for them. It offers treatment of asthma, allergies, and related diseases and conditions. The company also offers Twinject, an epinephrine auto-injector for anaphylaxis. Verus Pharmaceuticals is based in San Diego, California.

Roxy is a female sports fashion clothing brand based in Costa Mesa, California, specializing in an extensive range of apparel and accessories. The company offers an online shopping platform where customers can explore various product categories, including clothing, swimwear, footwear, and accessories. Roxy's collection features dresses, tops, tees, tanks, fleece, hoodies, jackets, pants, shorts, and loungewear, alongside a diverse selection of accessories such as handbags, backpacks, hats, and footwear options like sneakers, boots, and sandals. By providing a wide array of choices, Roxy caters to the fashion needs and preferences of its customers, promoting an active and stylish lifestyle.

eVentures Group operates and invests in internet communications companies.